Polymyxins as Novel and Safe Mucosal Adjuvants to Induce Humoral Immune Responses in Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yoshino, Naoto ^a   Endo, Masahiro ^a   Kanno, Hiroyuki ^a   Matsukawa, Naomi ^a   Tsutsumi, Reiko ^a   Takeshita, Ryosuke ^a   Sato, Shigehiro ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; COLISTIMETHATE; COLISTIN; HISTAMINE; IMMUNOLOGICAL ADJUVANT; OVALBUMIN; POLYMYXIN B; POLYMYXIN B NONAPEPTIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME RELEASE; FEMALE; HUMORAL IMMUNITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; MAST CELL DEGRANULATION; MOUSE; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTAMINE; IMMUNITY, HUMORAL; MICE; MICE, INBRED C57BL; OVALBUMIN; POLYMYXIN B; STATISTICS, NONPARAMETRIC;

MUS;

EID: 84876099076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061643     Document Type: Article

References (68)

1. Elson CO, Ealding W, (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132: 2736-2741.
2. Clements JD, Hartzog NM, Lyon FL, (1988) Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6: 269-277.
3. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, et al. (1997) A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 94: 5267-5272.
4. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
5. McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, et al. (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14: 536-541.
6. St John AL, Chan CY, Staats HF, Leong KW, Abraham SN, et al. (2012) Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater 11: 250-257.
7. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, et al. (2003) Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol 4: 1199-1205.
8. Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, et al. (2005) Bulfone-Paus S. TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood 106: 978-987.
9. Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, et al. (2008) Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci USA 105: 9313-9318.
10. Caron G, Delneste Y, Roelandts E, Duez C, Herbault N, et al. (2001) Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J Immunol 166: 6000-6006.
11. Amaral MM, Davio C, Ceballos A, Salamone G, Cañones C, et al. (2007) Histamine improves antigen uptake and cross-presentation by dendritic cells. J Immunol 179: 3425-3433.
12. Shelburne CP, Nakano H, St John AL, Chan C, McLachlan JB, et al. (2009) Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 6: 331-342.
13. Jawdat DM, Rowden G, Marshall JS, (2006) Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol 177: 1755-1762.
14. Finlay BB, Hancock RE, (2004) Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol 2: 497-504.
15. Hancock RE, (2001) Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1: 156-164.
16. Andreu D, Rivas L, (1998) Animal antimicrobial peptides: an overview. Biopolymers 47: 415-433.
17. Risso A, Zanetti M, Gennaro R, (1998) Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol 189: 107-115.
18. Gallo RL, Ono M, Povsic T, Page C, Eriksson E, et al. (1994) Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci USA 91: 11035-11039.
19. Gudmundsson GH, Agerberth B, (1999) Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods 232: 45-54.
20. Sawyer JG, Martin NL, Hancock RE, (1988) Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Immun 56: 693-698.
21. Stansly PG, Shepherd RG, White HJ, (1947) Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 81: 43-54.
22. Falagas ME, Kasiakou SK, (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40: 1333-1341.
23. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K, (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 25: 11-25.
24. Bushby SRM, Green AF, (1955) The release or histamine by polymyxin B and polymyxin E. Br J Pharmacol Chemother. 10: 215-219.
25. Parratt JR, West GB, (1957) Release of 5-hydroxytryptamine and histamine from tissues of the rat. J Physiol 137: 179-192.
26. Ellis HV 3rd, Johnson AR, Moran NC, (1970) Selective release of histamine from rat mast cells by several drugs. J Pharmacol Exp Ther 175: 627-631.
27. Voitenko VG, Bayramashvili DI, Zebrev AI, Zinchenko AA, (1990) Relationship between structure and histamine releasing action of polymyxin B and its analogues. Agents Actions 30: 153-156.
28. Lee C, Chen D, Nagel EL, (1977) Neuromuscular block by antibiotics: polymyxin B. Anesth Analg. 56: 373-377.
29. Hagiwara Y, Kawamura YI, Kataoka K, Rahima B, Jackson RJ, et al. (2006) A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol 177: 3045-3054.
30. Yoshino N, Fujihashi K, Hagiwara Y, Kanno H, Takahashi K, et al. (2009) Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 27: 4808-4817.
31. Yoshino N, Kanno H, Takahashi K, Endo M, Sato S, (2012) Mucosal immune responses in W/Wv and Sl/Sld mutant mice. Exp Anim 61: 407-416.
32. Wu HY, Russell MW, (1993) Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 61: 314-322.
33. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, et al. (1996) Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156: 3892-3900.
34. Moldoveanu Z, Fujihashi K (2005) Collection and processing of external secretions and tissues of mouse origin. In: Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, et al. editors. Mucosal Immunology 3rd ed, San Diego: Academic Press. pp. 1841-1852.
35. Kweon MN, Yamamoto M, Watanabe F, Tamura S, van Ginkel FW, et al. (2002) A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 186: 1261-1269.
36. Galli SJ, Dvorak AM, Marcum JA, Ishizaka T, Nabel G, et al. (1982) Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol 95: 435-444.
37. Schwartz LB, Riedel C, Caulfield JP, Wasserman SI, Austen KF, (1981) Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J Immunol 126: 2071-2078.
38. Kawamoto S, Kaneoke M, Ohkouchi K, Amano Y, Takaoka Y, et al. (2011) Sake lees fermented with lactic acid bacteria prevents allergic rhinitis-like symptoms and IgE-mediated basophil degranulation. Biosci Biotechnol Biochem 75: 140-144.
39. Appelmelk BJ, Su D, Verweij-van Vught AM, Thijs BG, MacLaren DM, (1992) Polymyxin B-horseradish peroxidase conjugates as tools in endotoxin research. Anal Biochem 207: 311-316.
40. Saita T, Yoshida M, Nakashima M, Matsunaga H, Fujito H, et al. (1999) A highly sensitive ELISA for the quantification of polymyxin B sulfate in human serum. Biol Pharm Bull 22: 1257-1261.
41. Tallgren LG, Liewendahl K, Kuhlbaeck B, (1965) The therapeutic success and nephrotoxicity of colistin in acute and chronic nephrotoxicity with impaired renal function. Acta Med Scand 177: 717-728.
42. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, et al. (1970) Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72: 857-868.
43. Fekety FR Jr, Norman PS, Cluff LE, (1962) The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 57: 214-229.
44. Katz R, (1963) Renal and possibly hepatic toxicity from colymycin. Report of a case. Med Ann Dist Columbia 32: 408-413.
45. Ito J, Johnson WW, Roy S 3rd, (1969) Colistin nephrotoxicity: report of a case with light and electron microscopic studies. Acta Pathol Jpn 19: 55-67.
46. Alving CR, (1933) Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187: 430-446.
47. Rosenstreich DL, Glode LM, (1975) Difference in B cell mitogen responsiveness between closely related strains of mice. J Immunol 115: 777-780.
48. Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, et al. (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189: 615-625.
49. Chihara S, Tobita T, Yahata M, Ito A, Koyana Y, (1973) Enzymatic degradation of colistin, isolation and identification of α-N-acetyl α,γ-diaminobutyric acid and colistin nonapeptide. Agric Biol Chem 37: 2455-2463.
50. Beveridge EG, Martin AJ, (1967) Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 29: 125-135.
51. Ascarateil S, Dupuis L (2006) Surfactants in vaccine adjuvants: description and perspectives. Vaccine (Suppl 2): 83-85.
52. Kosaric N, (1992) Biosurfactants in industry. J Am Oil Chem Soc 64: 1731-1737.
53. Cameotra S, Makkar R, (1998) Synthesis of biosurfactants in extreme conditions. Appl Microbiol Biotechnol 50: 520-529.
54. Hashizume H, Nishimura Y, (2008) Cyclic lipopeptide antibiotics. Stud Nat Prod Chem 35: 693-751.
55. Reis e Sousa C, Germain RN, (1999) Analysis of adjuvant function by direct visualization of antigen presentation in vivo: endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue. J Immunol 162: 6552-6561.
56. Ohmura M, Yamamoto M, Kiyono H, Fujihashi K, Takeda Y, et al. (2001) Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin. Vaccine 20: 756-762.
57. Tough DF, Sun S, Sprent J, (1997) T cell stimulation in vivo by lipopolysaccharide (LPS). J Exp Med 185: 2089-2094.
58. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P, (1998) Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 188: 2175-2180.
59. Lycke N, (1997) The mechanism of cholera toxin adjuvanticity. Res Immunol 148: 504-520.
60. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, et al. (2002) Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 46: 1946-1952.
61. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, et al. (1987) Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19: 831-838.
62. Littlewood JM, Koch C, Lambert PA, Hoiby N, Elborn JS, et al. (2000) A ten year review of colomycin. Respir Med 94: 632-640.
63. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, et al. (2001) Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 84: 432-433.
64. Katz SL, Ho SL, Coates AL, (2001) Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 119: 250-255.
65. Hodson ME, Gallagher CG, Govan JR, (2002) A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20: 658-664.
66. Schwartz BS, Warren MR, Barkley FA, Landis L, (1959-1960) Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiot Annu 7: 41-60.
67. Falagas ME, Sideri G, Korbila IP, Vouloumanou EK, Papadatos JH, et al. (2010) Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 45: 1135-1140.
68. Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, et al. (2010) Colistin administration to pediatric and neonatal patients. Eur J Pediatr 169: 867-874.